By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
AlloVir is advancing a pipeline of allogeneic, off-the-shelf, virus-specific T cell therapies to prevent or treat life-threatening viral diseases
Partner with Us
We welcome discussions with industry, government and non-profit organizations about potential partnership and licensing opportunities that can facilitate and expedite the delivery of our therapies to patients in need, including:
Global and regional licensing opportunities across our pipeline, including our investigational SARS-CoV-2 specific VST therapy, ALVR109
Co-development or co-commercialization partnerships
Research and development collaborations to explore new indications, new patient populations, or new applications for our VST platform
To discuss partnering with AlloVir, please submit an inquiry to: bd@allovir.com
Ongoing Partnerships
Baylor College of Medicine
Our technology platform was developed by world-class scientists at the Baylor College of Medicine’s Center for Cell and Gene Therapy. We continue to collaborate on basic and translational research of novel cell therapies through sponsored research agreements.
AlloVir is the global leader in developing VST immunotherapies
We develop highly innovative, allogeneic, off-the-shelf, virus-specific T cell (VST) therapies designed to prevent and treat life-threatening viral diseases.
Our Pipeline
Our allogeneic, off-the-shelf VST therapy candidates target 11 different devastating viruses as treatment or prevention.
AlloVir does not control and is not responsible for the content on the website you are about to visit. AlloVir is providing this link as a convenience, and this link does not imply AlloVir’s endorsement of any material on the website you are about to visit. Do you wish to continue?
AlloVir does not control and is not responsible for the content on the website you are about to visit. AlloVir is providing this link as a convenience, and this link does not imply AlloVir’s endorsement of any material on the website you are about to visit. Do you wish to continue?
AlloVir does not control and is not responsible for the content on the website you are about to visit. AlloVir is providing this link as a convenience, and this link does not imply AlloVir’s endorsement of any material on the website you are about to visit. Do you wish to continue?
An Allogeneic, Off-the-Shelf Virus Specific T-cell Product That Demonstrates Reactivity Against a Broad Range of SARS-CoV-2 Variant Strains and Fills an Unmet Need for Vulnerable Patients
Preclinical data for ALVR109 show retained activity against a broad range of SARS-CoV-2 variants, including Omicron
